drugset / Trial / NCT00125021
Tarceva and Capecitabine for Pancreatic Cancer
Phase 2
Completed
32 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabGenentech, Inc. · collabMassachusetts General Hospital · collabRoche Global Development · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase II trial is designed to investigate the effectiveness of Tarceva (OSI-774) combined with capecitabine in treating patients with metastatic pancreatic cancer.
Timeline
- Start
- 2003-10
- Primary completion
- 2004-06
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Erlotinib | Small molecule | — | — |